Workflow
Drug targets for allergic diseases
icon
Search documents
Novartis inks $1.7 billion drug target agreement with UK’s Relation Therapeutics (NVS:NYSE)
Seeking Alpha· 2025-12-09 06:36
Novartis AG (NVS) to pay UK biotech Relation Therapeutics Ltd. as much as $1.7 billion to help find drug targets to treat allergic diseases. The deal aims to combine Novartis’s (NVS) expertise in immuno-dermatology with the British firm’s drug discovery ...